Jan 11, 2024 8:30am EST Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
Jan 09, 2024 8:30am EST Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
Jan 04, 2024 9:05am EST Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide
Nov 28, 2023 9:10am EST Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
Nov 27, 2023 9:05am EST Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study
Nov 01, 2023 8:30am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
Oct 31, 2023 8:31am EDT Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Oct 13, 2023 9:05am EDT Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn